Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3691483 | 0.98 | GAA (0.49) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL3765199 | 0.82 | GAA (0.50) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL7526296 | 0.82 | GAA (0.50) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL22127756 | 0.80 | GAA (0.49) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL241284 | 0.80 | KMT2A (0.50) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL30022335 | 0.78 | GAA (0.48) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL22127835 | 0.78 | GAA (0.48) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL19186393 | 0.78 | GAA (0.48) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL23355263 | 0.77 | GAA (0.47) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL21163241 | 0.77 | GAA (0.47) | GAAHTTL3MBTL1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2120942-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | Othera Holding, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20070197599-A1 | HYDROXYLAMINES AND DERIVATIVES AS ANTI-ANGIOGENIC AGENTS | COLBY PHARMACEUTICAL COMPANY | 2007-08-23 | — | — | US | disclosed |
| WO-2007092741-A2 | HYDROXYLAMINES AND DERIVATIVES AS ANTI-ANGIOGENIC AGENTS | OTHERA HOLDING, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20060292190-A1 | Amelioration of vitrectomy-induced cataracts | OTHERA PHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
| WO-2006127592-A2 | USE OF HYDROXYLAMINE DERIVATES FOR INHIBITING VITRECTOMY-INDUCED CATARACTS | OTHERA PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1689354-A2 | AMELIORATION OF CATARACTS, MACULAR DEGENERATION AND OTHER OPHTHALMIC DISEASES | Othera Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005055926-A2 | AMELIORATION OF CATARACTS, MACULAR DEGENERATION AND OTHER OPHTHALMIC DISEASES | OTHERA PHARMACEUTICALS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | COLBY PHARMACEUTICAL COMPANY | 2005-06-16 | — | — | US | disclosed |
| EP-1507826-A2 | AMELIORATION OF THE DEVELOPMENT OF CATARACTS AND OTHER OPTHALMIC DISEASES | Othera Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040002461-A1 | Amelioration of the development of cataracts and other ophthalmic diseases | COLBY PHARMACEUTICAL COMPANY | 2004-01-01 | — | — | US | disclosed |
| WO-2003096991-A2 | AMELIORATION OF THE DEVELOPMENT OF CATARACTS AND OTHER OPTHALMIC DISEASES | OTHERA PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197599-A1 | HYDROXYLAMINES AND DERIVATIVES AS ANTI-ANGIOGENIC AGENTS | FLT4, VEGFA, HDGF | GAA 1189/4885HTT 257/4885L3MBTL1 2506/4885 |
| US-20060292190-A1 | Amelioration of vitrectomy-induced cataracts | CRYAB, CRYAA, VIM | GAA 1847/4885HTT 15/4885L3MBTL1 4291/4885 |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | C3AR1, C1R, AKR1C3 | GAA 4032/4885HTT 57/4885L3MBTL1 1725/4885 |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | C1R, CRYAB, C9 | GAA 4234/4885HTT 331/4885L3MBTL1 1963/4885 |
| US-20040002461-A1 | Amelioration of the development of cataracts and other ophthalmic diseases | PDE6D, PDE6H, CCR1 | GAA 3517/4885HTT 115/4885L3MBTL1 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.